-
Featured
Immunotherapies to Treat Glioblastoma
William T. Curry, MD, co-director of Mass General Neuroscience and director of Neurosurgical Oncology in the Department of Neurosurgery at Massachusetts General Hospital, discusses a four-center trial studying the use of poliovirus to treat malignant brain tumors.
-
Review: Checkpoint Inhibitors and Other Immunotherapies in Urologic Cancer
Aleksandra Walasek, MD, and Dimitar V. Zlatev, MD, discuss progress in immunotherapies for urologic cancers, showing checkpoint inhibitors are often first-line therapy, combination regimens are improving outcomes, and antibody–drug conjugates are becoming new options for dual-refractory bladder cancer.
-
Activating CD4+ T Cells at Benign Nevi Might Prevent Melanoma
Shadmehr Demehri, MD, PhD, Erik B. Schiferle, and colleagues determined benign nevi harbor CD4+ T cells that can be activated in situ to reject the nevus. If a novel therapy could block immunosuppressive regulatory T cells, CD4+ cells might prevent progression to melanoma in high-risk patients and enhance immunotherapy.
-
Designing Leading-Edge Immunotherapy for Brain Cancer
New immunotherapy for brain cancer tackles the barrier of tumor heterogeneity using a home-grown combination of CAR T-cell therapy and bispecific antibodies.
-
Combination Checkpoint Inhibitor Therapy Safe, Extends Survival for Leptomeningeal Disease
In a phase 2 trial, researchers at the Massachusetts General Hospital Cancer Center observed that the combination of two immune checkpoint inhibitors, ipilimumab and nivolumab, was safe and associated with three-month overall survival of 44% in a heavily pretreated population of patients with leptomeningeal disease.
-
Immune Cell Hubs Interact with Malignant Cells in Human Colorectal Cancer
Nir Hacohen, PhD, of the Massachusetts General Hospital Cancer Center, and colleagues developed a novel systematic approach to mapping the immune microenvironment of colorectal cancer and found multicellular interaction networks that may influence response to immunotherapy.
Mass General Cancer Center Contributors
-
Areej R. El-Jawahri, MD
Hematologist, Mass General Cancer Center, Assistant in Medicine, Massachusetts General Hospital, Instructor in Medicine, Harvard Medical School
Recent Article
Improved Coping Explains Benefits of Integrated Palliative Care for Patients With Acute Myeloid Leukemia
-
Chin-Lee Wu, MD, PhD
Director, Genitourinary Pathology Service, Massachusetts General Hospital and Mass General Cancer Center, Professor of Pathology, Harvard Medical School
Recent Article
Combined Standard and Targeted Transperineal Biopsies Advised for Patients With Prostate Lesion on Multiparametric MRI
-
Justin F. Gainor, MD
Director, Center for Thoracic Cancers, Mass General Cancer Center, Director of Targeted Immunotherapy, Assistant Professor of Medicine, Harvard Medical School
Recent Article
About the Henri and Belinda Termeer Center for Targeted Therapies at the Mass General Cancer Center
-
Michael L. Dougan, MD, PhD
Physician, Division of Gastroenterology, Massachusetts General Hospital, Director, GI Center for Cancer Complications, Mass General Cancer Center, Assistant Professor of Medicine, Harvard Medical School
Recent Article
Bamlanivimab–Etesevimab for Mild to Moderate COVID-19 in Patients at High Risk of Progression
-
William T. Curry, MD
Co-Director, Mass General Neuroscience , Director of Neurosurgical Oncology, Massachusetts General Hospital, Adeline Rose Wydotis Professor of Neurosurgery, Harvard Medical School
Recent Article
Novel Tandem CAR T-Cell Effective Against Heterogeneous Glioblastoma
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
